PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35264157-12 2022 Further study showed that metformin blocked the cells in G1 phase by inducing phosphorylated YAP1 and reducing the expression of cyclin D1, CDK6, CDK4 and RB, which enhanced the chemosensitivity of cisplatin and activated the expression of cleaved caspase 3 in TGCTs. Cisplatin 198-207 cyclin dependent kinase 4 Homo sapiens 146-150 35270034-9 2022 Altogether, our study has demonstrated the potency of a novel CDK4/6 and PARP dual inhibitor, which can potentially be developed into a monotherapy or combinatorial therapy with cisplatin for breast and ovarian cancer patients with HR proficiency. Cisplatin 178-187 cyclin dependent kinase 4 Homo sapiens 62-68 33534964-2 2021 We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. Cisplatin 111-120 cyclin dependent kinase 4 Homo sapiens 66-72 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 114-123 cyclin dependent kinase 4 Homo sapiens 36-40 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 114-123 cyclin dependent kinase 4 Homo sapiens 62-66 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 114-123 cyclin dependent kinase 4 Homo sapiens 62-66 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 125-129 cyclin dependent kinase 4 Homo sapiens 36-40 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 125-129 cyclin dependent kinase 4 Homo sapiens 62-66 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 125-129 cyclin dependent kinase 4 Homo sapiens 62-66 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 159-163 cyclin dependent kinase 4 Homo sapiens 62-66 34036394-7 2021 In order to elucidate the effect of CDK4 on drug sensitivity, CDK4-overexpressing OS cell lines were treated with cisplatin (CDDP); significant attenuation of CDDP sensitivity, demonstrated by increased cell viability and decreased expression of cleaved caspase-9, was induced by enforced expression of CDK4. Cisplatin 159-163 cyclin dependent kinase 4 Homo sapiens 62-66 33676835-0 2021 Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib. Cisplatin 0-9 cyclin dependent kinase 4 Homo sapiens 89-95 26993269-2 2016 In this study, we further explored the molecular function and mechanism of CDK4 modulating miRNAs to stimulate cell cycle transition, cell growth, and Cisplatin (DDP) -resistance on in NPC. Cisplatin 151-160 cyclin dependent kinase 4 Homo sapiens 75-79 32418994-3 2020 In this study, we analysed the potential of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib (PaRi) as molecular drugs to treat cisplatin-resistant and -sensitive paediatric and adult GCTs. Cisplatin 154-163 cyclin dependent kinase 4 Homo sapiens 44-71 32418994-3 2020 In this study, we analysed the potential of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib (PaRi) as molecular drugs to treat cisplatin-resistant and -sensitive paediatric and adult GCTs. Cisplatin 154-163 cyclin dependent kinase 4 Homo sapiens 73-79 32229099-6 2020 Interestingly, AKI triggered by the anti-cancer drug cisplatin can be mitigated by ribociclib, a CDK4/6 inhibitor, through mechanisms that remain unclear. Cisplatin 53-62 cyclin dependent kinase 4 Homo sapiens 97-103 32229099-9 2020 Furthermore, we find that cisplatin treatment evokes CDK4/6 activation and Rb1 phosphorylation in the normally quiescent RTECs, however, this is not followed by S-phase entry likely due to DNA-damage induced G1 arrest. Cisplatin 26-35 cyclin dependent kinase 4 Homo sapiens 53-59 33061853-13 2020 Western blot analysis revealed that PD enhanced sensitivity to CDDP through the CDK4/6-cyclin D1-RB-E2F pathway. Cisplatin 63-67 cyclin dependent kinase 4 Homo sapiens 80-86 33061853-14 2020 Conclusions: Pre-treatment with PD synchronized the tumour cell cycle through the CDK4/6-cyclin D1-RB-E2F pathway, which increased the antitumour effect of CDDP. Cisplatin 156-160 cyclin dependent kinase 4 Homo sapiens 82-88 31727874-0 2019 Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cisplatin 0-9 cyclin dependent kinase 4 Homo sapiens 56-62 30242024-3 2019 We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP). Cisplatin 86-95 cyclin dependent kinase 4 Homo sapiens 29-35 30242024-3 2019 We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP). Cisplatin 97-101 cyclin dependent kinase 4 Homo sapiens 29-35 26993269-2 2016 In this study, we further explored the molecular function and mechanism of CDK4 modulating miRNAs to stimulate cell cycle transition, cell growth, and Cisplatin (DDP) -resistance on in NPC. Cisplatin 162-165 cyclin dependent kinase 4 Homo sapiens 75-79 26575528-12 2016 In KKU-100 cells, growth inhibition was accompanied by upregulation of p53 and p21 and downregulation of CDK4 and Bcl-2 due to exposure to cisplatin, SAHA and TSA alone or in combination. Cisplatin 139-148 cyclin dependent kinase 4 Homo sapiens 105-109 18942709-8 2009 The role of nuclear factor-kappaB (NF-kappaB) and cyclin-dependent kinase 4 (CDK4) in cyclin D1-mediated cisplatin resistance was also examined. Cisplatin 105-114 cyclin dependent kinase 4 Homo sapiens 77-81 25703099-3 2015 The expression of cyclin-dependent kinase 6 (CDK6), a potential target of miR-145, was lower in resistant cells, and inhibition of CDK4/6 protected cells from cisplatin. Cisplatin 159-168 cyclin dependent kinase 4 Homo sapiens 131-137 25703099-16 2015 An inhibitor of CDK4/6 (PD0332991) protected parental NSCLC cells from cisplatin cytotoxicity. Cisplatin 71-80 cyclin dependent kinase 4 Homo sapiens 16-22 24338822-6 2014 Induction of transient G0/G1 cycle arrest through CDK4/6 inhibition protected hRPTC from DNA damage and caspase 3/7 activation following exposure to the nephrotoxins cisplatin, etoposide, and antimycin A. Cisplatin 166-175 cyclin dependent kinase 4 Homo sapiens 50-56 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 0-9 cyclin dependent kinase 4 Homo sapiens 43-47 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 123-132 cyclin dependent kinase 4 Homo sapiens 43-47